165 related articles for article (PubMed ID: 19654036)
21. Stem cell defects after cytoreductive therapy in man.
Schreml W; Lohrmann HP; Anger B
Exp Hematol; 1985; 13 Suppl 16():31-42. PubMed ID: 2985415
[TBL] [Abstract][Full Text] [Related]
22. Excretion of Ascaris lumbricoides during total body irradiation.
Jurcic JG; Koll B; Brown AE; Crown JP; Yahalom J; Gulati SC
Bone Marrow Transplant; 1994 Apr; 13(4):491-3. PubMed ID: 8019476
[TBL] [Abstract][Full Text] [Related]
23. Long-term marrow cultures from mice with busulfan-induced chronic latent aplasia.
Halka KG; Caro J; Erslev AJ
J Lab Clin Med; 1987 Jun; 109(6):698-705. PubMed ID: 3585143
[TBL] [Abstract][Full Text] [Related]
24. Early suppressive effects of chemotherapy and cytokine treatment on committed versus primitive haemopoietic progenitors in patient bone marrow.
Schwartz GN; Hakim F; Zujewski J; Szabo JM; Cepada R; Riseberg D; Warren MK; Mackall CL; Setzer A; Noone M; Cowan KH; O'Shaughnessy J; Gress RE
Br J Haematol; 1996 Mar; 92(3):537-47. PubMed ID: 8616014
[TBL] [Abstract][Full Text] [Related]
25. [Kinetics of circulating hematopoietic stem cells following chemotherapy in patients with hematopoietic malignancies].
Tamura K; Kosaka M; Mizuguchi T; Miyamoto Y
Rinsho Ketsueki; 1990 May; 31(5):647-54. PubMed ID: 1697629
[TBL] [Abstract][Full Text] [Related]
26. Effects of verapamil on etoposide, vincristine, and adriamycin activity in normal human bone marrow granulocyte-macrophage progenitors and in human K562 leukemia cells in vitro.
Yalowich JC; Zucali JR; Gross M; Ross WE
Cancer Res; 1985 Oct; 45(10):4921-4. PubMed ID: 3861238
[TBL] [Abstract][Full Text] [Related]
27. Development of latent residual drug damage to the hematopoietic marrow during the subsequent growth of tumors.
Kovacs CJ; Johnke RM; Evans MJ; Emma DA; Hooker JL
Exp Hematol; 1986 Mar; 14(3):165-72. PubMed ID: 3948928
[TBL] [Abstract][Full Text] [Related]
28. [Experimental bases of the in vitro treatment of leukemic bone marrow by a derivative of cyclophosphamide: ASTA Z 7557].
Douay L; Gorin NC; Mary JY; Duhamel G
C R Acad Sci III; 1985; 301(6):303-8. PubMed ID: 3928107
[TBL] [Abstract][Full Text] [Related]
29. Potential drugs for elimination of acute lymphatic leukemia cells from autologous bone marrow.
Blaauw A; Spitzer G; Dicke K; Drewinko B; Vellekoop L; Zander A
Exp Hematol; 1986 Aug; 14(7):683-8. PubMed ID: 2426131
[TBL] [Abstract][Full Text] [Related]
30. Range and clinical significance of the number of myeloid-committed stem cells in the blood of patients with acute leukaemia in remission.
Hinterberger W; Bettelheim P; Höcker P; Lechner K; Neumann E; Niessner H
Scand J Haematol; 1984 Sep; 33(3):244-51. PubMed ID: 6505626
[TBL] [Abstract][Full Text] [Related]
31. The in vitro effect of epirubicin on human normal and leukemic hemopoietic cells.
Bagnara GP; Rocchi P; Bonsi L; Valvassori L; Marini M; Prodi G
Anticancer Res; 1987; 7(6):1197-200. PubMed ID: 3481683
[TBL] [Abstract][Full Text] [Related]
32. A severe and consistent deficit in marrow and circulating primitive hematopoietic cells (long-term culture-initiating cells) in acquired aplastic anemia.
Maciejewski JP; Selleri C; Sato T; Anderson S; Young NS
Blood; 1996 Sep; 88(6):1983-91. PubMed ID: 8822917
[TBL] [Abstract][Full Text] [Related]
33. Both early and committed haemopoietic progenitors are more frequent in peripheral blood than in bone marrow during mobilization induced by high-dose chemotherapy + G-CSF.
Tarella C; Benedetti G; Caracciolo D; Castellino C; Cherasco C; Bondesan P; Omedé P; Ruggieri D; Gianni AM; Pileri A
Br J Haematol; 1995 Nov; 91(3):535-43. PubMed ID: 8555051
[TBL] [Abstract][Full Text] [Related]
34. Pure red cell aplasia associated with B cell lymphoma: demonstration of bone marrow colony inhibition by serum immunoglobulin.
Alter R; Joshi SS; Verdirame JD; Weisenburger DD
Leuk Res; 1990; 14(3):279-86. PubMed ID: 1690829
[TBL] [Abstract][Full Text] [Related]
35. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma.
McLaughlin P; Hagemeister FB; Swan F; Cabanillas F; Pate O; Romaguera JE; Rodriguez MA; Redman JR; Keating M
J Clin Oncol; 1994 Mar; 12(3):575-9. PubMed ID: 8120556
[TBL] [Abstract][Full Text] [Related]
36. Myeloprotective effect of diethyldithiocarbamate treatment following 1,3-bis(2-chloroethyl)-1-nitrosourea, adriamycin, or mitomycin C in mice.
Schmalbach TK; Borch RF
Cancer Res; 1989 May; 49(10):2574-7. PubMed ID: 2540902
[TBL] [Abstract][Full Text] [Related]
37. Recombinant human interleukin-1 receptor antagonist protects early myeloid progenitors in a murine model of cyclophosphamide-induced myelotoxicity.
Chudgar UH; Rundus CH; Peterson VM
Blood; 1995 May; 85(9):2393-401. PubMed ID: 7727773
[TBL] [Abstract][Full Text] [Related]
38. Long-term bone-marrow damage in children treated for ALL: evidence from in vitro colony assays (GM-CFC and CFUF).
Haworth C; Morris-Jones PH; Testa NG
Br J Cancer; 1982 Dec; 46(6):918-23. PubMed ID: 6960924
[TBL] [Abstract][Full Text] [Related]
39. Effect of misonidazole therapy on human granulopoietic stem cells.
Allalunis MJ; Turner AR; Partington JP; Urtasun RC
Cancer Treat Rep; 1980; 64(10-11):1097-102. PubMed ID: 7459895
[TBL] [Abstract][Full Text] [Related]
40. Determinants of the optimal first-line therapy for follicular lymphoma: a decision analysis.
Olin RL; Kanetsky PA; Ten Have TR; Nasta SD; Schuster SJ; Andreadis C
Am J Hematol; 2010 Apr; 85(4):255-60. PubMed ID: 20196173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
